{"id":55864,"date":"2026-01-30T12:15:02","date_gmt":"2026-01-30T04:15:02","guid":{"rendered":"https:\/\/flcube.com\/?p=55864"},"modified":"2026-04-10T23:39:45","modified_gmt":"2026-04-10T15:39:45","slug":"roche-reports-7-sales-growth-to-chf-61-5b-driven-by-pharma-and-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55864","title":{"rendered":"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China"},"content":{"rendered":"\n<p><strong>Roche<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROG:SWX\">SWX:\u202fROG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS:\u202fRHHBY<\/a>) reported full\u2011year 2025 sales of <strong>CHF\u202f61.5\u202fbillion<\/strong> : (<strong>USD\u202f69.1\u202fbillion<\/strong>), representing <strong>7% growth<\/strong> at constant exchange rates (CER), driven by robust pharmaceutical performance and strong emerging market expansion, particularly in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-financial-performance\">Key Financial Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Division<\/th><th>2025 Sales (CHF)<\/th><th>USD Equivalent<\/th><th>CER Growth<\/th><th>CHF Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Group Total<\/strong><\/td><td>61.5\u202fbillion<\/td><td>69.1\u202fbillion<\/td><td>+7%<\/td><td>+2%<\/td><\/tr><tr><td><strong>Pharmaceuticals<\/strong><\/td><td>47.7\u202fbillion<\/td><td>53.6\u202fbillion<\/td><td>+9%<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Diagnostics<\/strong><\/td><td>13.8\u202fbillion<\/td><td>15.5\u202fbillion<\/td><td>+2%<\/td><td>-3%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Note:<\/strong> All growth figures quoted at constant exchange rates (CER) unless otherwise stated.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pharmaceutical-growth-drivers\">Pharmaceutical Growth Drivers<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Indication<\/th><th>2025 Sales (CHF)<\/th><th>CER Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Ocrevus<\/strong><\/td><td>Multiple sclerosis<\/td><td>7,010\u202fmillion<\/td><td>+9%<\/td><\/tr><tr><td><strong>Hemlibra<\/strong><\/td><td>Hemophilia A<\/td><td>4,754\u202fmillion<\/td><td>+11%<\/td><\/tr><tr><td><strong>Vabysmo<\/strong><\/td><td>Retinal diseases<\/td><td>4,102\u202fmillion<\/td><td>+12%<\/td><\/tr><tr><td><strong>Xolair<\/strong><\/td><td>Severe allergic diseases<\/td><td>3,075\u202fmillion<\/td><td>+32%<\/td><\/tr><tr><td><strong>Phesgo<\/strong><\/td><td>HER2\u2011positive breast cancer<\/td><td>2,441\u202fmillion<\/td><td>+48%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Combined Impact:<\/strong> These five products generated <strong>CHF\u202f21.4\u202fbillion<\/strong> in sales, accounting for a <strong>CHF\u202f3.2\u202fbillion CER increase<\/strong> year\u2011on\u2011year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regional-performance-amp-china-market\">Regional Performance &amp; China Market<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>United States:<\/strong> Pharmaceuticals sales <strong>+8%<\/strong>, driven by Ocrevus and Hemlibra<\/li>\n\n\n\n<li><strong>Europe &amp; Japan:<\/strong> Both regions delivered <strong>+5%<\/strong> growth<\/li>\n\n\n\n<li><strong>International (including China):<\/strong> <strong>+14%<\/strong> overall, with <strong>China +10%<\/strong> supported by NRDL inclusion of Phesgo and uptake of Xofluza, Vabysmo, and Polivy<\/li>\n\n\n\n<li><strong>Diagnostics Asia\u2011Pacific:<\/strong> Declined <strong>12%<\/strong>, reflecting China healthcare pricing reforms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-progress-amp-2026-outlook\">Pipeline Progress &amp; 2026 Outlook<\/h2>\n\n\n\n<p><strong>2025 Milestones:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>US &amp; EU approvals<\/strong> for subcutaneous Lunsumio in follicular lymphoma<\/li>\n\n\n\n<li><strong>EU approval<\/strong> of Gazyva for lupus nephritis<\/li>\n\n\n\n<li><strong>Positive data<\/strong> for SERD giredestrant in ER\u2011positive breast cancer and BTK inhibitor fenebrutinib in multiple sclerosis<\/li>\n\n\n\n<li><strong>10 molecules<\/strong> advanced to Phase\u202fIII development<\/li>\n<\/ul>\n\n\n\n<p><strong>2026 Guidance:<\/strong> Roche expects <strong>mid\u2011single\u2011digit sales growth<\/strong> and <strong>high\u2011single\u2011digit core EPS growth<\/strong> at CER.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding 2026 guidance, pipeline development, and market growth. Actual results may differ due to competitive dynamics, pricing pressures, and macroeconomic factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) reported full\u2011year 2025 sales of CHF\u202f61.5\u202fbillion : (USD\u202f69.1\u202fbillion), representing 7% growth at&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55865,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[16,20,83,940,74,163,939],"class_list":["post-55864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cancer","tag-finance","tag-her2","tag-otcmkts-rhhby","tag-rdl","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) reported full\u2011year 2025 sales of CHF\u202f61.5\u202fbillion : (USD\u202f69.1\u202fbillion), representing 7% growth at constant exchange rates (CER), driven by robust pharmaceutical performance and strong emerging market expansion, particularly in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55864\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China\" \/>\n<meta property=\"og:description\" content=\"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) reported full\u2011year 2025 sales of CHF\u202f61.5\u202fbillion : (USD\u202f69.1\u202fbillion), representing 7% growth at constant exchange rates (CER), driven by robust pharmaceutical performance and strong emerging market expansion, particularly in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55864\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T04:15:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-10T15:39:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China\",\"datePublished\":\"2026-01-30T04:15:02+00:00\",\"dateModified\":\"2026-04-10T15:39:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3001.webp\",\"keywords\":[\"Cancer\",\"Finance\",\"HER2\",\"OTCMKTS: RHHBY\",\"RDL\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55864#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55864\",\"name\":\"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3001.webp\",\"datePublished\":\"2026-01-30T04:15:02+00:00\",\"dateModified\":\"2026-04-10T15:39:45+00:00\",\"description\":\"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) reported full\u2011year 2025 sales of CHF\u202f61.5\u202fbillion : (USD\u202f69.1\u202fbillion), representing 7% growth at constant exchange rates (CER), driven by robust pharmaceutical performance and strong emerging market expansion, particularly in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55864\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55864#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China - Insight, China&#039;s Pharmaceutical Industry","description":"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) reported full\u2011year 2025 sales of CHF\u202f61.5\u202fbillion : (USD\u202f69.1\u202fbillion), representing 7% growth at constant exchange rates (CER), driven by robust pharmaceutical performance and strong emerging market expansion, particularly in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55864","og_locale":"en_US","og_type":"article","og_title":"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China","og_description":"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) reported full\u2011year 2025 sales of CHF\u202f61.5\u202fbillion : (USD\u202f69.1\u202fbillion), representing 7% growth at constant exchange rates (CER), driven by robust pharmaceutical performance and strong emerging market expansion, particularly in China.","og_url":"https:\/\/flcube.com\/?p=55864","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-30T04:15:02+00:00","article_modified_time":"2026-04-10T15:39:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55864#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55864"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China","datePublished":"2026-01-30T04:15:02+00:00","dateModified":"2026-04-10T15:39:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55864"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55864#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3001.webp","keywords":["Cancer","Finance","HER2","OTCMKTS: RHHBY","RDL","Roche","SWX: ROP"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55864#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55864","url":"https:\/\/flcube.com\/?p=55864","name":"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55864#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55864#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3001.webp","datePublished":"2026-01-30T04:15:02+00:00","dateModified":"2026-04-10T15:39:45+00:00","description":"Roche (SWX:\u202fROG, OTCMKTS:\u202fRHHBY) reported full\u2011year 2025 sales of CHF\u202f61.5\u202fbillion : (USD\u202f69.1\u202fbillion), representing 7% growth at constant exchange rates (CER), driven by robust pharmaceutical performance and strong emerging market expansion, particularly in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55864#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55864"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55864#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3001.webp","width":1080,"height":608,"caption":"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55864#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche Reports 7% Sales Growth to CHF 61.5B, Driven by Pharma and China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55864"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55864\/revisions"}],"predecessor-version":[{"id":55866,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55864\/revisions\/55866"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55865"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}